Anti-IL-5 for Severe Asthma: Aiming High to Achieve Success

Affiliations

¹ Department of Infection, Immunity and Inflammation, Institute for Lung Health, Glenfield Hospital, University of Leicester, Leicester, England.
² Department of Infection, Immunity and Inflammation, Institute for Lung Health, Glenfield Hospital, University of Leicester, Leicester, England. Electronic address: ceb17@le.ac.uk.

Editorial

Richard Russell et al. Chest. 2016 Oct.

. 2016 Oct;150(4):766-768.

doi: 10.1016/j.chest.2016.06.013.

¹ Department of Infection, Immunity and Inflammation, Institute for Lung Health, Glenfield Hospital, University of Leicester, Leicester, England.
² Department of Infection, Immunity and Inflammation, Institute for Lung Health, Glenfield Hospital, University of Leicester, Leicester, England. Electronic address: ceb17@le.ac.uk.

No abstract available

Comment on

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Corren J, et al. Chest. 2016 Oct;150(4):799-810. doi: 10.1016/j.chest.2016.03.018. Epub 2016 Mar 25. Chest. 2016. PMID: 27018175 Clinical Trial.
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Bjermer L, et al. Chest. 2016 Oct;150(4):789-798. doi: 10.1016/j.chest.2016.03.032. Epub 2016 Apr 4. Chest. 2016. PMID: 27056586 Clinical Trial.